What they were paid
Blueprint Medicines Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2024 | $72,900 | $237,966 | $261,724 | $0 | $572,590 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Blueprint Medicines Corp DEF 14A filed April 24, 2025, accession 0001558370-25-005415, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2024Blueprint Medicines pays directors a $50,000 cash retainer.
Committees
FY2024 · as the proxy prints themAudit · Nominating/Governance (Chair)
The rest of the Blueprint Medicines board
FY2024 · as the company reported each| Director | Role | FY2024 total |
|---|---|---|
| Alexis Borisy | Independent Director | $549,690 |
| Daniella Beckman | Independent Director | $574,690 |
| Habib Dable | Independent Director | $564,990 |
| Jeffrey W. Albers | Chair of the Board | $586,190 |
| John Tsai | Independent Director | $549,690 |
| Kathryn Haviland | Director | $0 |
| Lynn Seely | Lead Independent Director | $606,190 |
| Mark Goldberg | Independent Director | $586,690 |
| Nicholas Lydon | Independent Director | $569,690 |
The full Blueprint Medicines compensation record
free company briefThis page is one director within Blueprint Medicines's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat